MedTrace Logo

Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors

NCT01957995 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2017-04-11

No results posted yet for this study

Summary

This randomized phase I trial studies the side effects and best dose of nanosomal docetaxel lipid suspension in treating patients with advanced solid tumors. Drugs used in chemotherapy, such as nanosomal docetaxel lipid suspension, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

nanosomal docetaxel lipid suspension

Given IV

OTHER

pharmacological study

Correlative studies

Sponsors & Collaborators

  • Jina Pharmaceuticals Inc.

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Anthony El-Khoueiry · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-08
Primary Completion
2014-05-29
Completion
2016-07-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01957995 on ClinicalTrials.gov